Pfizer Inc. (PFE)
| Market Cap | 135.71B |
| Revenue (ttm) | 63.83B |
| Net Income (ttm) | 10.75B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.89 |
| PE Ratio | 12.60 |
| Forward PE | 8.45 |
| Dividend | $1.72 (7.21%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 81,374,931 |
| Open | 24.81 |
| Previous Close | 24.86 |
| Day's Range | 23.84 - 24.84 |
| 52-Week Range | 20.92 - 30.43 |
| Beta | 0.46 |
| Analysts | Hold |
| Price Target | 29.36 (+23.0%) |
| Earnings Date | Oct 28, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $29.36, which is an increase of 23.00% from the latest price.
News
Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine
Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively.
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 d...
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report comes as Health and Human Se...
Trump officials to link child deaths to covid shots, according to reports
CNBC's Angelica Peebles joins 'Money Movers' to discuss Trump officials reported plan to link child deaths to covid shots.
Pfizer's Comeback Accelerates
Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion, driven by Abrysvo RSV vaccine and Seagen-acquired oncology assets. Management expects over $20 billion in risk-adjusted reve...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Trump's Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.
The effort falls well short of banning the ads outright, but could dent sales.
Why The Market Is Dangerously Wrong About Pfizer Stock
Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum despite negative market sentiment and recent stock underperformance. Aggressive cost-cuttin...
Scoop Up These 3 Bargain-Bin Dividend Stocks
Today, we'll be highlighting PFE, YORW, and UPS. The trio offers a market-crushing 5.8% yield, an A- blended S&P credit rating, and is trading 21% below fair value estimates. Pfizer appears to have th...
Pfizer, partner BioNTech say updated COVID shot shows better immune response
Pfizer and partner BioNTech said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlyi...
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial...
Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks
Despite pressure from HHS Secretary RFK Jr. and pessimism from retail investors, Pfizer Inc.'s COVID-19 franchise sales were $808 million in Q2 2025, up 81.2% year-on-year. In addition, its oncology a...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Pfizer defends Covid-19 vaccine effectiveness after Trump remarks
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news from the pharmaceutical sector.
Pfizer defends COVID-19 vaccine effectiveness after Trump remarks
Pfizer on Wednesday defended the effectiveness of its COVID-19 vaccine, saying it has saved more than 14 million lives worldwide, after U.S. President Donald Trump urged pharmaceutical companies to ju...
Pfizer: Pipeline Monetization Shows Great Promise - Rich Yields Pending Re-Rating
PFE has shown great efforts in operational efficiencies, as observed in the richer profit margins, the expanding cash flows, and the healthier balance sheet. This is on top of its new pipelines/ partn...
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in...
Trump tells drugmakers to 'justify the success' of Covid meds after FDA limits vaccine approval
President Donald Trump called on pharmaceutical companies to "justify the success" of their Covid drugs days after the FDA set new limits on who can receive vaccines for the virus. Trump last week fir...
8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August Report
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
Taking Profits For Yield And Growth With David Alton Clark
David Alton Clark, The Winter Warrior Investor, thinks the market is a little bit toppy with stretched valuations. Focusing on high-conviction positions, trimming the number of holdings, and reallocat...